(NASDAQ: SRPT) Sarepta Therapeutics's forecast annual revenue growth rate of -16.92% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.68%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.94%.
Sarepta Therapeutics's revenue in 2025 is $2,481,531,000.On average, 10 Wall Street analysts forecast SRPT's revenue for 2025 to be $203,941,234,134, with the lowest SRPT revenue forecast at $191,479,253,105, and the highest SRPT revenue forecast at $226,952,162,502. On average, 10 Wall Street analysts forecast SRPT's revenue for 2026 to be $150,284,733,346, with the lowest SRPT revenue forecast at $103,108,880,906, and the highest SRPT revenue forecast at $222,514,995,282.
In 2027, SRPT is forecast to generate $149,634,059,562 in revenue, with the lowest revenue forecast at $93,411,115,325 and the highest revenue forecast at $243,710,994,253.